DRG Epidemiology’s coverage of herpes zoster (HZ) comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets. We report the incidence of HZ for each country, as well as annualized case counts projected to the national population.
Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.
DRG Epidemiology’s HZ forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living withHZ?
- Of all people with HZ, how many in each country have been formally diagnosed?
- Of all people diagnosed with HZ, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HZ over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following HZ patient populations:
- Total prevalent cases.
- Diagnosed prevalent cases.
… and many more (details available on request).
Note: Coverage may vary by country and region.
- Herpes Zoster - Epidemiology - Mature Markets Data
- Key Findings
- Introduction Graphics
- Incidence of Herpes Zoster per 1,000 per Year Among People of All Ages in 2018 and 2038
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Events of Herpes Zoster over the Next 20 Years
- Number of Diagnosed Incident Events of Herpes Zoster Avoided over 2018-2038 in the Countries Under Study due to Trends in Risk
- Key Findings
- Epidemiology Data
- Diagnosed Incident Events
- Diagnosed Recurrent Events
- Total Diagnosed Events
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Herpes Zoster
- Studies Excluded from the Analysis of Herpes Zoster
- Risk/Protective Factors
- Risk/Protective Factors for Herpes Zoster
- Literature Review
Author(s): Dr. Ravdeep Kaur, MPH; Alison Isherwood, MSc, MRes, PhD
Ravdeep Kaur started working in Decision Resources Inc. as an associate epidemiologist since December 31st, 2015.
She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period.
She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets.
She holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from Rajiv Gandhi University of Health Sciences, India. She also has a Fellowship in Heath care Technology Assessment from World health Organization (WHO), India office.
Prior to joining Decision Resources, Ravdeep worked as a Consultant in Reproductive, Maternal, Child and Adolescent Health Program in a United States Agency for International development (USAID) funded project.
Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.